Research Articles
DOI DOI: 10.62063/ecb-40

Identification of new candidate molecules against SARS-CoV-2 through docking studies

Punar Aliyeva1, Beyza Yilmaz1, Doruk Alp Uzunarslan2, Vildan Enisoglu Atalay3
  1. 1 Üsküdar University
  2. 2 Uskudar American Academy
  3. 3 Istanbul Technical University

Abstract

The recent outbreak of a new coronavirus disease known as COVID-19, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is a highly contagious and pathogenic viral infection that has spread worldwide. Coronaviruses are known to cause disease in humans, other mammals, and birds. Although specific therapeutics and vaccines require efforts in this direction, reaching the world's population with mutations of the virus can be a difficult target. The major proteases of coronavirus play a critical role during the spread of the disease and therefore still represent an important target for drug discovery. As of now, there is still no official treatment for infected patients. In this study, bioinformatics-based molecular docking studies were performed to identify potent inhibitors of novel candidate molecules against the spike protein S of SARS-CoV-2. The affinities of ligand molecules thought to be effective in the treatment of SARS-CoV-2 disease were investigated. For this purpose, 1,615 different FDA-approved drug ligand molecules were retrieved from ZINC15 database. Crystallographic structure of spike protein S of SARS-CoV-2 was retrieved from Protein Data Bank (PDB). Initial virtual screening was performed using qvina-w, an accelerated version of AutoDock Vina optimized for rapid docking, to evaluate binding affinities of all 1,615 compounds against the spike protein. The top 10 ligands with the most favorable binding affinities were selected for further analysis. These ligands were docked to the target protein with Autodock Vina. The complexes were first solvated and then run through Molecular Dynamics (MD) simulations, utilizing NAMD. The binding energies were computed through these interactions, which are used to compare the affinities of the ligands to the target protein. Ultimately, 10 different ligands capable of inhibiting the spike protein of SARS-CoV-2 were selected and compared based on their affinities.

How to Cite

Aliyeva, P., Yilmaz, B., Uzunarslan, D. A., & Enisoglu Atalay, V. (2025). Identification of new candidate molecules against SARS-CoV-2 through docking studies. The European Chemistry and Biotechnology Journal, (4), 14–23. https://doi.org/10.62063/ecb-40
Endnote/Zotero/Mendeley (RIS) BibTeX

References

  1. Armstrong, J., Niemann, H., Smeekens, S., Rottier, P., & Warren, G. (1984). Sequence and topology of a model intracellular membrane protein, E1 glycoprotein, from a coronavirus. Nature, 308(5961), 751–752. https://doi.org/10.1038/308751a0
  2. Beniac, D. R., Andonov, A., Grudeski, E., & Booth, T. F. (2006). Architecture of the SARS coronavirus prefusion spike. Nature Structural & Molecular Biology, 13(8), 751–752. https://doi.org/10.1038/nsmb1123
  3. Bestle, D., Heindl, M. R., Limburg, H., Pilgram, O., Moulton, H., Stein, D. A., Hardes, K., Eickmann, M., Dolnik, O., Rohde, C., Klenk, H. D., Garten, W., Steinmetzer, T., & Böttcher-Friebertshäuser, E. (2020). TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Science Alliance, 3(9), e202000786. https://doi.org/10.26508/lsa.202000786
  4. Bhattacharya, S., Banerjee, A., & Ray, S. (2021). Development of new vaccine target against SARS-CoV2 using envelope (E) protein: An evolutionary, molecular modeling and docking based study. International Journal of Biological Macromolecules, 172, 74–81. https://doi.org/10.1016/j.ijbiomac.2020.12.192
  5. Bosch, B. J., Van der Zee, R., De Haan, C. A., & Rottier, P. J. (2003). The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex. Journal of Virology, 77(16), 8801–8811. https://doi.org/10.1128/JVI.77.16.8801-8811.2003
  6. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
  7. Eberhardt, J., Santos-Martins, D., Tillack, A. F., & Forli, S. (2021). AutoDock Vina 1.2.0: New docking methods, expanded force field, and python bindings. Journal of Chemical Information and Modeling, 61(8), 3891–3898. https://doi.org/10.1021/acs.jcim.1c00203
  8. Fehr, A. R., & Perlman, S. (2015). Coronaviruses: An overview of their replication and pathogenesis. In H. J. Maier, E. Bickerton, & P. Britton (Eds.), Coronaviruses: Methods and Protocols (pp. 1–23). Humana Press. https://doi.org/10.1007/978-1-4939-2438-7_1
  9. Frenoy, P., Perduca, V., Cano-Sancho, G., Antignac, J. P., Severi, G., & Mancini, F. R. (2022). Application of two statistical approaches (Bayesian Kernel Machine Regression and Principal Component Regression) to assess breast cancer risk in association to exposure to mixtures of brominated flame retardants and per- and polyfluorinated alkylated substances in the E3N cohort. Environmental Health, 21(1), 27. https://doi.org/10.1186/s12940-022-00817-0
  10. Garg, M., Maralakunte, M., Garg, S., Dhooria, S., Sehgal, I., Bhalla, A. S., Vijayvergiya, R., Grover, S., Bhatia, V., Jagia, P., Bhalla, A., Suri, V., Goyal, M., Agarwal, R., Puri, G. D., & Sandhu, M. S. (2021). The conundrum of 'Long-COVID-19': A narrative review. International Journal of General Medicine, 14, 2491–2506. https://doi.org/10.2147/IJGM.S316708
  11. Hamming, I., Timens, W., Bulthuis, M. L. C., Lely, A. T., Navis, G. V., & van Goor, H. (2004). Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology, 203(2), 631–637. https://doi.org/10.1002/path.1570
  12. Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD - Visual Molecular Dynamics. Journal of Molecular Graphics, 14(1), 33–38. https://doi.org/10.1016/0263-7855(96)00018-5
  13. Hurst, K. R., Koetzner, C. A., & Masters, P. S. (2013). Characterization of a critical interaction between the coronavirus nucleocapsid protein and nonstructural protein 3 of the viral replicase-transcriptase complex. Journal of Virology, 87(16), 9159–9172. https://doi.org/10.1128/JVI.01075-13
  14. Kamimura, A., Umemoto, H., Kawamoto, T., & Honda, T. (2021). Development of water solubility of 2-phenylsulfanylhydroquinone dimer dye. ACS Omega, 6(13), 9254–9262. https://doi.org/10.1021/acsomega.1c00507
  15. Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews Drug Discovery, 3(11), 935–949. https://doi.org/10.1038/nrd1549
  16. Kumawat, P., Agarwal, L. K., & Sharma, K. (2024). An overview of SARS-CoV-2 potential targets, inhibitors, and computational insights to enrich the promising treatment strategies. Current Microbiology, 81, 169. https://doi.org/10.1007/s00284-024-03615-1
  17. Kuo, L., & Masters, P. S. (2013). Functional analysis of the murine coronavirus genomic RNA packaging signal. Journal of Virology, 87(9), 5182–5192. https://doi.org/10.1128/JVI.03478-12
  18. Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., & Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 581(7807), 215–220. https://doi.org/10.1038/s41586-020-2180-5
  19. Letko, M., Marzi, A., & Munster, V. (2020). Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature Microbiology, 5(4), 562–569. https://doi.org/10.1038/s41564-020-0688-y
  20. Li, Y., Surya, W., Claudine, S., & Torres, J. (2014). Structure of a conserved Golgi complex-targeting signal in coronavirus envelope proteins. Journal of Biological Chemistry, 289(18), 12535–12549. https://doi.org/10.1074/jbc.M113.528487
  21. Molinspiration. (2015). Calculation of molecular properties and bioactivity score. http://www.molinspiration.com/cgi-bin/properties
  22. Neuman, B. W., Kiss, G., Kunding, A. H., Bhella, D., Baksh, M. F., Connelly, S., Droese, B., Klaus, J. P., Makino, S., & Buchmeier, M. J. (2011). A structural analysis of M protein in coronavirus assembly and morphology. Journal of Structural Biology, 174(1), 11–22. https://doi.org/10.1016/j.jsb.2010.11.021
  23. Nieto-Torres, J. L., DeDiego, M. L., Verdiá-Báguena, C., Jimenez-Guardeño, J. M., Regla-Nava, J. A., Fernandez-Delgado, R., Castano-Rodriguez, C., Alcaraz, A., Torres, J., Aguilella, V. M., & Enjuanes, L. (2014). Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathogens, 10(5), e1004077. https://doi.org/10.1371/journal.ppat.1004077
  24. Payne, S. (2017). Family Coronaviridae. In Viruses (pp. 149–158). Academic Press. https://doi.org/10.1016/B978-0-12-803109-4.00017-9
  25. Petersen, E., Koopmans, M., Go, U., Hamer, D. H., Petrosillo, N., Castelli, F., Storgaard, M., Al Khalili, S., & Simonsen, L. (2020). Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. The Lancet Infectious Diseases, 20(9), e238–e244. https://doi.org/10.1016/S1473-3099(20)30484-9
  26. Phillips, J. C., Hardy, D. J., Maia, J. D. C., Stone, J. E., Ribeiro, J. V., Bernardi, R. C., Buch, R., Fiorin, G., Hénin, J., Jiang, W., McGreevy, R., Melo, M. C. R., Radak, B. K., Skeel, R. D., Singharoy, A., Wang, Y., Roux, B., Aksimentiev, A., Luthey-Schulten, Z., Kalé, L. V., Schulten, K., Chipot, C., & Tajkhorshid, E. (2020). Scalable molecular dynamics on CPU and GPU architectures with NAMD. The Journal of Chemical Physics, 153(4), 044130. https://doi.org/10.1063/5.0014475
  27. Rarey, M., Wefing, S., & Lengauer, T. (1996). Placement of medium-sized molecular fragments into active sites of proteins. Journal of Computer-Aided Molecular Design, 10(1), 41–54. https://doi.org/10.1007/BF00124466
  28. Rogers, D. M., Agarwal, R., Vermaas, J. V., Durrant, J. D., Welborn, V. V., Kireev, D., & Luthey-Schulten, Z. (2023). SARS-CoV2 billion-compound docking. Scientific Data, 10, 173. https://doi.org/10.1038/s41597-023-02148-0
  29. Schoeman, D., & Fielding, B. C. (2019). Coronavirus envelope protein: Current knowledge. Virology Journal, 16, 69. https://doi.org/10.1186/s12985-019-1182-0
  30. Sharma, V., Rai, H., Gautam, D. N. S., Prajapati, P. K., & Sharma, R. (2022). Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant. Journal of Medical Virology, 94(5), 1876–1885. https://doi.org/10.1002/jmv.27526
  31. Stohlman, S. A., & Lai, M. M. (1979). Phosphoproteins of murine hepatitis viruses. Journal of Virology, 32(2), 672–675. https://doi.org/10.1128/jvi.32.2.672-675.1979
  32. Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181(2), 281–292.e6. https://doi.org/10.1016/j.cell.2020.02.058
  33. Wang, Q., Qiu, Y., Li, J. Y., Zhou, Z. J., Liao, C. H., & Ge, X. Y. (2020). A unique protease cleavage site predicted in the spike protein of the novel pneumonia coronavirus (2019-nCoV) potentially related to viral transmissibility. Virologica Sinica, 35, 337–339. https://doi.org/10.1007/s12250-020-00206-5
  34. Wang, Y., Grunewald, M., & Perlman, S. (2020). Coronaviruses: An updated overview of their replication and pathogenesis. In H. J. Maier, E. Bickerton, & P. Britton (Eds.), Coronaviruses: Methods and Protocols (pp. 1–29). Humana. https://doi.org/10.1007/978-1-0716-0327-7_1
  35. Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., Qin, C., Sun, F., Shi, Z., Zhu, Y., Jiang, S., & Lu, L. (2020). Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Research, 30(4), 343–355. https://doi.org/10.1038/s41422-020-0305-x
  36. Xiu, S., Dick, A., Ju, H., Mirzaie, S., Abdi, F., Cocklin, S., Zhan, P., & Liu, X. (2020). Inhibitors of SARS-CoV-2 entry: Current and future opportunities. Journal of Medicinal Chemistry, 63(21), 12256–12274. https://doi.org/10.1021/acs.jmedchem.0c00502